Iveric Bio Inc - ISEE STOCK NEWS

Iveric Bio, Inc. (NASDAQ: ISEE) announced on September 1, 2021, that it granted equity-based awards to three new non-executive employees under its 2019 Inducement Stock Incentive Plan. The grants include non-statutory options for 155,000 shares at an exercise price of $10.45, reflecting the stock's closing price on the grant date. The options vest over four years, with initial vesting on September 1, 2022, and subsequent monthly vesting. Additionally, the company granted 12,500 restricted stock units, which will vest fully on September 1, 2022, contingent on continued employment.

IVERIC bio (Nasdaq: ISEE) will feature President Pravin U. Dugel, M.D. at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021. His presentation will be available on-demand from 7:00 a.m. ET, alongside a live panel discussion titled Addressing Unmet Medical Needs in Macular Degeneration at 11:00 a.m. ET. Investors can tune in via the Iveric Bio website, where an archived replay will be provided for 30 days post-conference. The company focuses on therapies for retinal diseases, including age-related and inherited conditions.

IVERIC bio (Nasdaq: ISEE) will have its President, Pravin U. Dugel, M.D., participate in a panel on Ophthalmic Gene Therapy at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11 at 8:00 a.m. ET. The event is open to investors and the public via live webcast on the company's website, with an archived replay available for 30 days thereafter. Iveric bio focuses on developing treatments for retinal diseases, with both therapeutic and gene therapy product candidates addressing significant unmet medical needs.

IVERIC bio, Inc. (Nasdaq: ISEE) reported Q2 2021 financial results, highlighting significant progress in their Zimura clinical program. The company received a Special Protocol Assessment from the FDA for the GATHER2 trial and completed patient enrollment four months ahead of schedule, targeting over 90% retention. They strengthened their balance sheet with a public offering, raising ~$108 million. However, they incurred a net loss of $30.1 million for the quarter. Cash reserves are projected between $215 million and $225 million by year-end 2021, sufficient to fund operations through mid-2024.

IVERIC bio, Inc. (Nasdaq: ISEE) announced the grant of equity-based awards on August 2, 2021, to five newly hired employees as part of its 2019 Inducement Stock Incentive Plan. Significant awards include a non-statutory option to purchase 160,000 shares and restricted stock units totaling 90,000 for Senior VP Christopher Simms, with vesting over various periods. The exercise price for options is set at $8.64 per share, reflecting the stock's closing price on the grant date. These grants aim to incentivize employee retention and align interests.

IVERIC bio, Inc. (Nasdaq: ISEE) will report its Q2 2021 financial results on August 4, 2021. Following the announcement, management will host a live conference call at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Participants can dial in to join or access the audio webcast on the company’s website. Iveric is focused on developing treatments for retinal diseases, including therapeutic and gene therapy candidates for specific conditions.

IVERIC bio (Nasdaq: ISEE) announced the early completion of patient enrollment for the GATHER2 clinical trial of Zimura (avacincaptad pegol), aimed at treating geographic atrophy secondary to age-related macular degeneration. Enrollment was completed four months ahead of schedule, signaling a strong patient need amid the challenges of the COVID-19 pandemic. Topline data is expected in H2 2022, contingent on meeting primary endpoints. The FDA has provided a Special Protocol Assessment for GATHER2, bolstering plans for marketing application if results are favorable.

IVERIC bio, Inc. (Nasdaq: ISEE) appointed Christopher Simms as Senior Vice President and Chief Commercial Officer, effective August 2, 2021. Simms, previously with Novartis, will focus on developing and implementing the company’s commercial strategy, particularly for Zimura^® in the upcoming GATHER2 clinical trial and potential new drug application. His extensive experience in ophthalmology is expected to aid in establishing a successful AMD franchise. Iveric is dedicated to advancing retinal disease treatments, and Simms' appointment marks a pivotal step in transitioning to a commercial organization.

IVERIC bio, Inc. (Nasdaq: ISEE) announced a public offering of 11,650,000 shares at $8.60 each, raising about $100.2 million before expenses. An option for underwriters to purchase an additional 1,747,500 shares is included. The offering is managed by Cowen, Credit Suisse, and Stifel, with expected closing on July 15, 2021. This move aims to bolster funding for the company’s development of treatments for retinal diseases. All shares are offered by the Company, and the prospectus will be filed with the SEC.